コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ranging from 31% for any leukemia to 89% for female breast cancer.
2 e breast cancer resembled that of late-onset female breast cancer.
3 y, male breast cancer is often compared with female breast cancer.
4 s for radiotherapy, by stage, are similar to female breast cancer.
5 r information for comparison with studies of female breast cancer.
6 predisposition to ovarian cancer as well as female breast cancer.
7 of which had a family history of male and/or female breast cancer.
8 ng cancer, and 0.88 (95% CI: 0.56, 1.39) for female breast cancer.
9 y of cancer are established risk factors for female breast cancer.
10 stases in an immune-competent mouse model of female breast cancer.
11 es in excess relative and absolute risk from female breast cancer.
12 cess relative and absolute risks of male and female breast cancers.
13 etiology of male breast cancers, similar to female breast cancers.
14 cancers, female breast cancer, and bilateral female breast cancers.
15 lele from XCI offers a potential therapy for female breast cancers.
16 esearch tool and a potential therapeutic for female breast cancers.
17 tion of FOXP3 in various cell lines of human female breast cancers.
18 CHEK2 had three times the population risk of female breast cancer (145 cases: SIR 3.48 (95% CI 2.96-4
19 e 80 years were 53% (95% CI, 44% to 63%) for female breast cancer, 5% (95% CI, 2% to 10%) for ovarian
20 n-associated relative risk for male than for female breast cancer, although absolute excess risks for
21 ds in the age-adjusted incidence of invasive female breast cancer and compared these with trends in t
22 rphism was associated with increased risk of female breast cancer and may modify the relation between
23 ed for any cancer, multiple primary cancers, female breast cancer, and bilateral female breast cancer
24 nown associations of ionizing radiation with female breast cancer, and emerging evidence also for mal
25 s showed a >100-fold higher risk of sarcoma, female breast cancer, and hematologic malignancies for t
26 nts (ozone and PM(2.5)) and prostate cancer, female breast cancer, and melanoma of the skin across mu
27 of families with multiple case, early onset female breast cancer, and they are also associated with
31 ed significantly over time for both male and female breast cancer, but progress for men has lagged be
32 ome-wide association study data from 172,737 female breast cancer cases and 242,009 controls of Afric
33 quencing data of BRCA1 and BRCA2 from 96,691 female breast cancer cases and 302,116 controls from thr
34 ge-matched case-control study identified 735 female breast cancer cases and 735 female controls witho
35 s analyzed data from a case-control study of female breast cancer conducted in Connecticut in 1994-19
36 al benefit was concentrated in patients with female breast cancer (DD, 1.20 ppt; 95%CI, 0.27 to 2.12)
37 notypically, there is evidence that male and female breast cancer differ in their molecular landscape
38 gram collected 600,000+ in situ and invasive female breast cancers during the years 1950 to 2003.
41 iver, stomach, kidney, lung, colorectal, and female breast cancers had higher incidence rates among A
44 ecrease in the overall incidence of invasive female breast cancer in the United States was reported.
45 D exposure domains for colorectal, lung, and female breast cancer incidence cumulatively over time us
48 ely, of relative risk for male compared with female breast cancer incidence, the former borderline si
50 interaction activates an ACC->BLA circuit in female breast cancer model mice, reducing anxiety, norep
51 rs conducted a retrospective analysis of (a) female breast cancer mortality rates from NCHS data for
53 the investigation of birth cohort trends in female breast cancer mortality rates obtained from the N
56 , 95% confidence interval (CI) = 1.29-1.46), female breast cancer (OR = 1.42, 95% CI = 1.27-1.58), th
57 anic White patients with male breast cancer, female breast cancer, or ovarian cancer who underwent te
58 ated the current and future global burden of female breast cancer overall, and by age group, in 185 c
59 focus group feedback, was administered to 95 female breast cancer participants twice within 1 to 2 we
60 s were established from blood samples of 100 female breast cancer patients and 105 healthy controls.
61 spanic, African American, and Asian American female breast cancer patients compared with non-Hispanic
62 ial (mtSNPs) and nuclear (nuSNPs) genomes of female breast cancer patients in The Cancer Genome Atlas
63 28F heterozygotes were 2.88% (47/1632) among female breast cancer patients not selected for family hi
64 t diagnosis was investigated in over 106,000 female breast cancer patients reported during 1992-1996
65 and Kaplan-Meier plot suggest that the TCGA female breast cancer patients with low gene expression o
66 in a population-based, multiethnic series of female breast cancer patients younger than 65 years at d
67 uclear cells of healthy donors or metastatic female breast cancer patients, induce robust, sustained
70 nd leukemia for both sexes; corpus uteri and female breast cancer; prostate cancer), for three age gr
71 demiologic findings on cigarette smoking and female breast cancer risk may reflect insufficient asses
72 ociated with an increased rate of subsequent female breast cancer (RR, 3.7; 95% CI, 1.8 to 7.7), espe
73 d associations between PALB2 PVs and risk of female breast cancer (RR, 7.18; 95% CI, 5.82 to 8.85; P
75 Of the 4 screening-detected cancers, only female breast cancer showed significant recovery in 2021
76 9.51; 95% CI, 1.15 to 34.37; P = .009), and female breast cancer (SIR, 3.95; 95% CI, 1.59 to 8.13; P
77 Eligibility criteria in both cohorts were female breast cancer survivors (stage I-III) aged 20-84
79 ucted a prospective cohort analysis in 3,223 female breast cancer survivors from five racial/ethnic p
80 ticles describing exercise communication for female breast cancer survivors in any geographical locat
85 in the home, is associated with the risk of female breast cancer, the authors analyzed data from a p
88 vestigated in a nested case-control study of female breast cancer within a cohort of African American